The Global Pharmaceutical Logistics Market Will Experience an Increase in Demand for Home Healthcare Products Through 2019
The Global Pharmaceutical Logistics Market is expected to grow at a CAGR of 9.71% from 2015–2019, according to a new report from research firm Technavio.
Many pharmaceutical logistics companies are now focusing on the expansion of their services and product portfolio to meet the global demand for home healthcare. Patients can easily use portable devices to check their blood pressure, glucose levels and other vital signs at home.
“The growth of the home healthcare segment has been a key factor in initiating several business and supply chain changes and is expected to drive growth in the pharmaceutical logistics sector over the next 10 years,” says Faisal Ghaus, Vice President of Technavio.
The Technavio report also highlights new methods of pharmaceutical delivery. Vendors are changing their transportation mode from air to sea for the delivery of medicines and drugs because of certain advantages, including a 70–80% reduction in cost.
Additionally, more vendors are relying on online services to deliver pharmaceutical products to patients. “Vendors have enhanced the use of online services like e-health records, remote monitoring, e-prescribing and mobile health applications, so as to ensure an effortless and quick delivery of medicines directly to patients,” says Ghaus.
Key Information Covered in the Report include:
• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
• Increased Demand for Home Healthcare Products
• For a full detailed list, view the report.
• Market Challenges:
• Inefficient Product Labeling
• Market Trends:
• New Methods of Pharmaceuticals Delivery
• Key Vendors:
• DB Schenker
• Deutsche Post DHL
• FedEx
• United Parcel Service of America Inc.
• Other Prominent Vendors:
• Agility
• Biocair
• CEVA
• Cold Chain Technologies
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.